Skip to Main content Skip to Navigation
Journal articles

Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

Abstract : CD47, an ubiquitously expressed innate immune checkpoint receptor that serves as a universal "don't eat me" signal of phagocytosis, is often upregulated by hematologic and solid cancers to evade immune surveillance. Development of CD47-targeted modalities is hindered by the ubiquitous expression of the target, often leading to rapid drug elimination and hemotoxicity including anemia. To overcome such liabilities, we have developed a fully human bispecific antibody, NI-1701, designed to coengage CD47 and CD19 selectively on B cells. NI-1701 demonstrates favorable elimination kinetics with no deleterious effects seen on hematologic parameters following single or multiple administrations to nonhuman primates. Potent in vitro and in vivo activity is induced by NI-1701 to kill cancer cells across a plethora of B-cell malignancies and control tumor growth in xenograft mouse models. The mechanism affording maximal tumor growth inhibition by NI-1701 is dependent on the coengagement of CD47/CD19 on B cells inducing potent antibody-dependent cellular phagocytosis of the targeted cells. NI-1701-induced control of tumor growth in immunodeficient NOD/SCID mice was more effective than that achieved with the anti-CD20 targeted antibody, rituximab. Interestingly, a synergistic effect was seen when tumor-implanted mice were coadministered NI-1701 and rituximab leading to significantly improved tumor growth inhibition and regression in some animals. We describe herein, a novel bispecific antibody approach aimed at sensitizing B cells to become more readily phagocytosed and eliminated thus offering an alternative or adjunct therapeutic option to patients with B-cell malignancies refractory/resistant to anti-CD20-targeted therapy.
Complete list of metadatas

Cited literature [49 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02474041
Contributor : Laurent Jonchère <>
Submitted on : Monday, March 23, 2020 - 10:22:00 AM
Last modification on : Monday, March 23, 2020 - 12:36:14 PM
Long-term archiving on: : Wednesday, June 24, 2020 - 1:20:42 PM

File

Buatois-2018-Preclinical Devel...
Files produced by the author(s)

Identifiers

Citation

Vanessa Buatois, Zoë Johnson, Susana Salgado-Pires, Anne Papaioannou, Eric Hatterer, et al.. Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. Molecular Cancer Therapeutics, American Association for Cancer Research, 2018, 17 (8), pp.1739-1751. ⟨10.1158/1535-7163.MCT-17-1095⟩. ⟨hal-02474041⟩

Share

Metrics

Record views

239

Files downloads

675